In Q1 2022, 18 biotech companies went public in the US, raising $4.2 billion. A year later, in Q1 2023, the number had collapsed to four IPOs raising $800 million. The IPO window had slammed shut — tighter than any period since the 2008 financial crisis.

By Q2 2026, 16 IPOs are projected to raise $5.0 billion. The recovery is U-shaped, not V-shaped, and it tells a specific story about how biotech capital markets work.

The IPO Cycle

The U-shape matters. V-shaped recoveries indicate that the underlying problem was temporary (a liquidity crunch, a geopolitical shock). U-shaped recoveries indicate something structural — in this case, investors' demand for clinical data before valuation. In 2021, biotech companies could IPO on preclinical data. In 2023-2026, they need Phase 2 results. That requirement adds 18-24 months to the IPO timeline, which is exactly what the U-shape captures.

Valuations by Therapeutic Area

Gene therapy commands the highest valuations — $1.1 billion average — despite having the fewest IPOs (12). This reflects the premium on platforms that promise one-time cures for genetic diseases, even though commercial execution has been slower than expected. Neurology ($920M) and immunology ($720M) follow, driven by the massive addressable markets in Alzheimer's, autoimmune diseases, and allergy.

Oncology has the most IPOs (28) but the lowest valuation among lead categories at $680 million. This is a mature category — investors know how to price oncology risk, and the premium for novelty is smaller.

What the IPO Data Tells Investors

Three patterns emerge from the 2024-2026 IPO data:

Platform companies are valued less than pipeline companies. Recursion went public at $1.2B in 2017 as a platform company. Its market cap in 2026 is ~$2.4B after merging with Exscientia. Compare that to a single-asset gene therapy company IPOing at $1.1B. The market still prices molecules above methods.

The IPO window is open but selective. Not every biotech with Phase 2 data goes public. Bankers are choosing quality over volume. Of the ~80 biotechs that raised Series C rounds in 2024, only 14 went public in 2025. The rest stayed private or got acquired.

Post-IPO performance is bifurcated. The 2024-2026 IPO cohort has winners (companies with approved or near-approved products, trading 2-5x above IPO price) and losers (companies with failed trials or platform-only stories, trading below cash value). The gap between the top and bottom quartile is larger than in any previous cycle.

The IPO market in 2026 is not the frothy market of 2021. It is a more disciplined, data-driven market where clinical results matter more than platform narratives. That is better for long-term investors, harder for early-stage companies, and a net positive for an industry that needed a reality check after the 2020-2021 bubble.

---

Data Sources: Renaissance Capital IPO database, BioPharma Dive M&A tracker (2024-2026), company SEC filings (S-1, 10-K, 8-K for each IPO and acquisition), EvaluatePharma patent cliff analysis.

About the Author: Martin DAVILA is a bioeconomy analyst and the founder of Bioinfometrics.